By Marie Rosenthal
Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood—and not a decrease in triglyceride levels as originally thought—appear to explain the reductions in cardiovascular (CV) events and deaths seen among people taking the prescription fish oil, icosapent ethyl (Vascepa, Amarin), according to a study that was presented at the American College of Cardiology’s Annual Scientific Sessions together with the World Congress of
APRIL 3, 2020